Sustained response to anlotinib in advanced pancreatic neuroendocrine carcinoma: A case report

Pancreatic neuroendocrine carcinoma (pNEC) is a type of pancreatic neuroendocrine neoplasm with a poor prognosis, and patients with metastatic pNEC have a survival time of only 8-12 months. The treatment options for pNEC are minimal, and the prognosis is unfavorable. The present study reports the case of a 56-year-old male who was diagnosed with advanced pNEC with bone metastases in June 2018. The patient was treated with oral anlotinib after eight cycles of first-line etoposide + cisplatin (EP) chemotherapy until July 2022. The adverse events that occurred during the treatment period were resolved with symptomatic management or drug dose reduction. At the time of writing this report, the patient's survival time was almost 60 months, which is rare for patients with pNEC. This case report suggests that patients with pNEC treated with first-line EP regimen chemotherapy may have a sustained response to anlotinib.